URL has been copied successfully!
GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have been on the market for a few years now. The medications are wildly popular, so it’s no surprise that other pharmaceutical companies like Pfizer and Amgen are trying to grab a piece of the market with similar drugs of their own.
In this week’s STATus Report, we’ll see how several pharma companies are trying to compete with Novo and Lilly’s already safe and effective products. We’ll also learn what Novo and Lilly are cooking up in order to stay dominant in the weight loss marketplace. And I drop in for a visit with my STAT colleagues from “The Readout LOUD” podcast for their thoughts on this head-spinning GLP-1 news cycle.
Please follow us:
